Jun
3
"'The key, I think, to the future of cancer drug development is to try to identify which patients are likely to respond and to do so in' early-stage clinical trials."
Ten years ago, targeted cancer treatments like Avastin and Herceptin were lauded as the silver bullets of chemotherapy. What we’ve learned since then is that for these targeted treatments to work, you have to closely match them to the precise genotype of a patient’s tumor (and, if I recall, in some cases of the patient, too). While this allows doctors to fine tuneĀ treatment for patients with tumors containing these mutations (making treatment more personalized), it means that the number of patients that can be helped (translated: the potential market) by any given targeted drug is that much smaller.